GENENTECH, INC for GENENTECH INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 20, 2018 | $980,000 | Replaced |
| 4th Quarter - Amendment | Apr 8, 2018 | $1,020,000 | Yes |
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Issues relating to drug pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| ANDREW WESLEY WOMACK | — |
Trade (domestic/foreign) TRD
Trade Policy Issues. Trade Negotiations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
| ANDREW WESLEY WOMACK | — |
Budget/Appropriations BUD
Issues related to FDA and HHS program funding in the FY18 Labor, Health and Human Services, and Education and Related Agencies, and FY18 Agriculture, Rural Development, Food and Drug Administrations, Related Agencies Appropriation bills
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Health Issues HCR
Medicare payment policies for Part B drugs. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program CHIP reauthorization and Medicare Extenders package. Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 S.204/H.R.878, Trickett Wendler Right to Try Act of 2017 H.J.Res.123, Making further continuing appropriations for fiscal year 2018, and for other purposes H.J.Res.124, Making further additional continuing appropriations for fiscal year 2018, and for other purposes H.R.1370, Further Additional Continuing Appropriations Act, 2018 Pharmaceutical benefits for TRICARE beneficiaries Issues related to pharmaceutical drug pricing Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Pharmaceutical distribution and supply chain security American Health Care Act of 2017 Issues relating to biosimilar reimbursement
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Taxation/Internal Revenue Code TAX
General tax issues. H.R. 1, Tax Cuts and Jobs Act. Tax Reform Act of 2017 - Issues related to tax reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
Copyright/Patent/Trademark CPT
Intellectual property and process patent issues. General IP issues. Patent litigation reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
Medicare/Medicaid MMM
Medicare payment policies for Part B drugs. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program CHIP reauthorization and Medicare Extenders package. Issues related to Medicare and Medicaid coverage and reimbursement; Issues relating to biosimilar reimbursement; Issues related to RX drug pricing. Medicare payment for inpatient antimicrobial therapy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Pharmacy PHA
Drug Pricing Issues Prescription Drug User Fee Act reauthorization. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.